Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
04
09
2018
accepted:
21
12
2018
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
epublish
Résumé
Primary biliary cholangitis (PBC) is an autoimmune liver disease that can lead to cirrhosis and liver failure. Our aim was to assess the recent trends in the mortality rates and health care utilization of patients with PBC seen in the inpatient setting in the United States. We used the National (Nationwide) Inpatient Sample data (2005-2014). The study population included adults with PBC, using International Classification of Diseases, Ninth Revision codes. Trends in PBC-related discharges, total charges, length of stay (LoS), and in-hospital mortality were evaluated. Hierarchical generalized linear models were performed for determining predictors of mortality and total hospital charges. Between the study years of 2005 and 2014, a total of 22,665 hospitalized cases with PBC were identified (mean age 63 years; 84% female, 76% white). The number of PBC-related discharges increased from 3.24 per 100,000 in 2005 to 3.68 per 100,000 in 2014, with an average annual increase of 1.4% (95% confidence interval [CI]: 0.4%-2.4%). Fifty-seven percent had Medicare as their primary payer, 37% had cirrhosis, and 1.3% had hepatocellular carcinoma. Between 2005 and 2014, the average total charges for PBC increased from $53,901 to $57,613 (annual percent change [APC], 1.7%; 95% CI: -0.2%-3.5%), LoS decreased from 6.9 days to 5.4 days (APC, -2.2%; 95% CI: -3.2% to -1.1%), and mortality rate decreased from 3.8% to 2.8% (APC, -5.4%; 95% CI: -8.4% to -2.4%). Multivariable analysis revealed that ascites were independently associated with increased risk of in-hospital mortality (odds ratio: 1.77; 95% CI: 1.50-2.08), increased charge (percent change: 22.5%; 95% CI: 18.6%-26.7%), and increased LoS (percent change: 29.7%; 95% CI: 25.7%-33.9%).
Identifiants
pubmed: 30859148
doi: 10.1002/hep4.1314
pii: HEP41314
pmc: PMC6396368
doi:
Types de publication
Journal Article
Langues
eng
Pagination
356-364Références
Hepatology. 1999 Mar;29(3):644-7
pubmed: 10051462
Hepatology. 1999 Aug;30(2):390-4
pubmed: 10421645
Gut. 2000 Jan;46(1):8
pubmed: 10601046
Eff Clin Pract. 2002 May-Jun;5(3):143-51
pubmed: 12088294
Gastroenterology. 2002 Oct;123(4):1044-51
pubmed: 12360466
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Hepatology. 2007 Sep;46(3):785-92
pubmed: 17680647
N Engl J Med. 2007 Oct 11;357(15):1524-9
pubmed: 17928600
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Trends Immunol. 2009 Aug;30(8):415-20
pubmed: 19643668
Hepatology. 2009 Dec;50(6):1884-92
pubmed: 19821525
World J Gastroenterol. 2010 Feb 28;16(8):973-81
pubmed: 20180236
Dis Markers. 2010;29(6):287-99
pubmed: 21297248
Clin Rev Allergy Immunol. 2012 Apr;42(2):199-212
pubmed: 21337133
Lancet. 2011 May 7;377(9777):1600-9
pubmed: 21529926
N Engl J Med. 2012 Oct 4;367(14):1355-60
pubmed: 23034025
Aliment Pharmacol Ther. 2013 Oct;38(7):794-803
pubmed: 23915021
J Gastroenterol. 2014 Oct;49(10):1414-20
pubmed: 24317935
Expert Opin Pharmacother. 2014 Feb;15(3):365-72
pubmed: 24382005
Liver Int. 2014 Jul;34(6):e31-8
pubmed: 24387641
Expert Rev Gastroenterol Hepatol. 2014 May;8(4):427-33
pubmed: 24580040
Trials. 2014 Jun 19;15:237
pubmed: 24947664
Semin Liver Dis. 2014 Aug;34(3):329-33
pubmed: 25057955
World J Hepatol. 2015 May 8;7(7):926-41
pubmed: 25954476
Gastroenterology. 2015 Dec;149(7):1804-1812.e4
pubmed: 26261009
Lancet. 2015 Oct 17;386(10003):1565-75
pubmed: 26364546
Expert Rev Clin Pharmacol. 2016;9(1):13-26
pubmed: 26549695
Dig Dis. 2015;33 Suppl 2:94-101
pubmed: 26641264
Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):650-659
pubmed: 27341761
Expert Opin Pharmacother. 2016 Sep;17(13):1809-15
pubmed: 27468093
Expert Rev Gastroenterol Hepatol. 2016 Oct;10(10):1091-1099
pubmed: 27589928
Hepatology. 2019 Jan;69(1):237-244
pubmed: 30015376
Hepatology. 1999 Jan;29(1):21-6
pubmed: 9862844